Mostrar el registro sencillo del ítem
| dc.contributor.author | Pons-Fuster, Eduardo | |
| dc.contributor.author | Martínez-Rodríguez, Rodrigo | |
| dc.contributor.author | Gimeno-Arias, Lourdes | |
| dc.contributor.author | Alcaraz, M-J | |
| dc.contributor.author | Moreno, Marta | |
| dc.contributor.author | Gómez, José-M | |
| dc.contributor.author | Peláez-Ballesta, Ana-Isabel | |
| dc.contributor.author | García, Elisa | |
| dc.contributor.author | Tomas, Cristina | |
| dc.contributor.author | Muñoz, Ángeles | |
| dc.contributor.author | V | |
| dc.contributor.author | Ruiz-Lorente, Inmaculada | |
| dc.contributor.author | Ceballos, Diana | |
| dc.contributor.author | Minguela-Puras, Alfredo | |
| dc.contributor.author | Bernal-Morell, Enrique | |
| dc.date.accessioned | 2026-03-10T11:49:10Z | |
| dc.date.available | 2026-03-10T11:49:10Z | |
| dc.date.issued | 2025-06 | |
| dc.identifier.citation | Pons-Fuster E, Martinez-Rodriguez R, Gimeno-Arias L, Alcaraz MJ, Moreno M, Gómez JM, et al. HLA-A*03 may confer protection against long COVID through an enhanced immune response. Infectious Diseases Now. junio de 2025;55(4):105057. doi:10.1016/j.idnow.2025.105057 | |
| dc.identifier.issn | 2666-9927 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/25214 | |
| dc.description.abstract | BACKGROUND: The COVID-19 pandemic has led to widespread infection, with a significant subset of patients developing persistent symptoms known as Long COVID. Understanding the genetic factors influencing Long COVID susceptibility and severity is crucial for development of targeted interventions. OBJECTIVE: This study aimed to evaluate the impact of HLA alleles, KIR receptors, and their interactions on the development of Long COVID in patients from southeastern Spain having contracted COVID-19 during the early 2020 pandemic wave. METHODS: A cross-sectional prospective study enrolled 153 COVID-19 patients. Three months post-infection, HLA-A, -B, -C, KIR genotyping and immunological variables were analyzed using serum and blood samples. Long COVID was diagnosed three years post- infection based on persistent symptoms. RESULTS: Among the participants, 71 developed Long COVID. HLA-A03 was less frequent in Long COVID compared to non-Long COVID patients (10.7 % vs. 30.5 %, p = 0.001). Patients with HLA-A03 had a higher percentage of CD8(+) T cells than patients with other allotypes (33.6 ± 13.4 % vs 28.7 ± 10.8 %, p = 0.033) and showed lower expression of KIR2DL1(1265 ± 547 vs 1465 ± 414 MFI, p = 0.031) and KIR3DL1 (300.6 ± 125.0 vs 398.9 ± 131.0 MFI, p = 0.047). Moreover, NK cells in HLA-A03 patients showed lower expression of the TIGIT inhibitory receptor (73.7 ± 12.2 % vs 78.2 ± 10.8 %, p = 0.046). CONCLUSION: HLA-A03 may play a protective role against Long COVID, potentially through enhanced immune responses involving CD8(+) T cells and NK cells. Further research in larger, diverse cohorts is needed to validate these findings and to refine personalized medicine strategies for managing COVID-19 sequelae. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | |
| dc.rights | Atribución/Reconocimiento 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/deed.es | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | COVID-19/immunology/genetics | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Cross-Sectional Studies | |
| dc.subject.mesh | Prospective Studies | |
| dc.subject.mesh | SARS-CoV-2/immunology | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | CD8-Positive T-Lymphocytes/immunology | |
| dc.subject.mesh | HLA-A3 Antigen/genetics/immunology | |
| dc.subject.mesh | Spain/epidemiology | |
| dc.subject.mesh | Receptors, KIR/genetics | |
| dc.subject.mesh | Killer Cells, Natural/immunology | |
| dc.subject.mesh | Alleles | |
| dc.subject.mesh | Genetic Predisposition to Disease | |
| dc.subject.mesh | Genotype | |
| dc.title | HLA-A*03 may confer protection against long COVID through an enhanced immune response | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 40107360 | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S2666991925000363 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1016/j.idnow.2025.105057 | |
| dc.journal.title | Infectious Diseases Now | |
| dc.identifier.essn | 2666-9919 |